ABL Diagnostics Plans Listing Transfer to Euronext Growth Paris

12:27 AM EDT, 08/10/2026 (MT Newswires) -- ABL Diagnostics (ABLD.PA) will seek shareholder approval to transfer its listing to the Euronext Growth Paris multilateral trading facility from the regulated market of Euronext Paris at a Sept. 17 meeting. The molecular diagnostic company aims to simplify its operations and lower regulatory limitations and costs through the transfer, expected to take place by Nov. 17 at the earliest, according to an Aug. 7 release. ABL expects to raise its free float to the minimum requirement of 2.5 million euros from 2.4 million euros at the time of the transfer.